株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市中肺炎(CAP):世界の治験レビュー

Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 320348
出版日 ページ情報 英文 207 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
市中肺炎(CAP):世界の治験レビュー Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017
出版日: 2017年06月30日 ページ情報: 英文 207 Pages
概要

市中肺炎(CAP)は、臨床医が対処する、最も一般的な感染症の1つです。CAPは、世界における死亡率と罹患率の重要な原因です。多くの病原体は、CAPを引き起こす可能性があります。症状を引き起こす代表的な細菌性病原体は、肺炎球菌(ペニシリン感受性、ペニシリン耐性株)、インフルエンザ菌(アンピシリン感受性、アンピシリン耐性株)、モラクセラ・カタラーリス(すべてはペニシリン耐性株)です。これら3つの病原体で、CAPの症例の約85%を占めています。CAPは通常、肺の1区域か肺葉に、肺の病原性細菌を吸入または吸引することで感染します。頻度は低いものの、大腸菌の尿路感染症や菌血症など、離れた場所の二次菌血症の結果として生じることもあります。誤嚥性肺炎は、複数の病原体(例えば、好気性/嫌気性の経口生物)に起因するCAPの唯一の形態です。

当レポートでは、市中肺炎(CAP)の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどについて、体系的な情報を提供しています。

目次

イントロダクション

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:感染性疾患の治験に対する市中肺炎(CAP)の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:感染性疾患の治験に対する市中肺炎(CAP)の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 市中肺炎(CAP)の治療薬の治験に参加している主要企業

有望薬

治験プロファイル

  • 主要企業の治験概要
    • Pfizer Inc.
    • TaiGen Biopharmaceuticals Holdings Limited
    • Sanofi
    • Actavis plc
    • Bayer AG
    • Melinta Therapeutics, Inc
    • Novartis AG
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Abbott Laboratories
  • 主要大学・研究機関・病院の治験概要
    • St. Antonius Hospital
    • University Hospital Basel
    • University of Milan
    • HaEmek Medical Center
    • Medical Center Alkmaar
    • Spanish National Health System
    • Carlos III Health Institute
    • Nagasaki Evaluation Organization for Clinical Interventions
    • 小野市立小野市民病院
    • University of Roma La Sapienza

主な臨床プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4322CTIDB

GlobalData's clinical trial report, "Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community Acquired Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community Acquired Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Community Acquired Pneumonia Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Latest Clinical Trials News on Community Acquired Pneumonia 36
  • May 30, 2017: TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the China Food and Drug Administration 36
  • Clinical Trial Profile Snapshots 37

Appendix 204

  • Abbreviations 204
  • Definitions 204
  • Research Methodology 205
  • Secondary Research 205
  • About GlobalData 206
  • Contact Us 206
  • Source 206

List of Tables

List of Tables

  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Community Acquired Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community Acquired Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36

List of Figures

List of Figures

  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Community Acquired Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community Acquired Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
  • GlobalData Methodology 206
Back to Top